HUP0402504A2 - Purinszármazékok, mint purinerg receptor antagonisták - Google Patents

Purinszármazékok, mint purinerg receptor antagonisták

Info

Publication number
HUP0402504A2
HUP0402504A2 HU0402504A HUP0402504A HUP0402504A2 HU P0402504 A2 HUP0402504 A2 HU P0402504A2 HU 0402504 A HU0402504 A HU 0402504A HU P0402504 A HUP0402504 A HU P0402504A HU P0402504 A2 HUP0402504 A2 HU P0402504A2
Authority
HU
Hungary
Prior art keywords
group
alkyl
general formula
aryl
hydrogen atom
Prior art date
Application number
HU0402504A
Other languages
English (en)
Inventor
Roger John Gillespie
Joanne Lerpiniere
Claire Elizabeth Dawson
Suneel Gaur
Robert Mark Pratt
Gemma Caroline Stratton
Scott Murray Weiss
Original Assignee
Vernalis Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Research Limited filed Critical Vernalis Research Limited
Publication of HUP0402504A2 publication Critical patent/HUP0402504A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A találmány tárgya (I) általános képletű vegyületek, ahol a képletbenR1 jelentése alkil-, aril-, alkoxi-, ariloxi-, tioalkil-, tioaril-,cianocsoport, halogénatom vagy NR5R6, NR4COR5, NR4CONR5R6, NR4CO2R7 ésNR4SO2R7 általános képletű csoport; R2 jelentése nitrogén-, oxigén-vagy kénatomot tartalmazó heteroarilcsoport, ahol a heteroarilcsoportolyan telítetlen szénatomon keresztül kapcsolódik, amely egy vagy kétnitrogén, oxigén vagy kénheteroatommal szomszédos, kivéve azorto,orto-diszubsztituált heteroarilcsoportokat, R3 jelentésehidrogénatom, alkilcsoport vagy COR8, CONR9R10, CONR8NR9R10, CO2R11 ésSO2R11 általános képletű csoport; R4, R5 és R6 jelentése egymástólfüggetlenül hidrogénatom, alkil- vagy arilcsoport vagy amikor R5 és R6egy (NR5R6) általános képletű csoport része, akkor R5 és R6összekapcsolódva heterociklusos csoportot alkothat, R7 jelentésealkil- vagy arilcsoport, R8, R9 és R10 jelentése egymástól függetlenülhidrogénatom, alkil- vagy arilcsoport, vagy R9 és R10 összekapcsolódvaheterociklusos csoportot alkothat, vagy amikor R8, R9 és R10 egy(CONR8NR9R10) általános képletű csoport része, akkor R8 és R9összekapcsolódva heterociklusos csoportot alkothat, és R11 jelentésealkil- vagy arilcsoport, vagy ezek gyógyszerészetileg alkalmazhatósója vagy elővegyülete alkalmazása gyógyszer előállításánál, amelyolyan rendellenesség megelőzésére vagy kezelésére szolgál, ahol apurin receptor, különösen az adenozin receptor, még közelebbről A2Areceptor blokkolása előnyös lehet. Ilyen rendellenességek például amozgási rendellenességek, így Parkinson-kór, depresszió, kognitív vagymemória-hanyatlás, akutos krónikus fájdalom. A találmány néhány új (I)általános képletű vegyületet is magában foglal. Ó
HU0402504A 2001-01-10 2002-01-10 Purinszármazékok, mint purinerg receptor antagonisták HUP0402504A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0100623.8A GB0100623D0 (en) 2001-01-10 2001-01-10 Chemical compounds IV
PCT/GB2002/000076 WO2002055521A1 (en) 2001-01-10 2002-01-10 Purine derivatives as purinergic receptor antagonists

Publications (1)

Publication Number Publication Date
HUP0402504A2 true HUP0402504A2 (hu) 2005-04-28

Family

ID=9906570

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402504A HUP0402504A2 (hu) 2001-01-10 2002-01-10 Purinszármazékok, mint purinerg receptor antagonisták

Country Status (22)

Country Link
US (2) US7452894B2 (hu)
EP (1) EP1349857B1 (hu)
JP (1) JP4284069B2 (hu)
KR (1) KR20030079945A (hu)
CN (1) CN1617871A (hu)
AT (1) ATE471323T1 (hu)
AU (1) AU2002217331B2 (hu)
BR (1) BR0206561A (hu)
CA (1) CA2433858C (hu)
CZ (1) CZ20031956A3 (hu)
DE (1) DE60236719D1 (hu)
GB (1) GB0100623D0 (hu)
HU (1) HUP0402504A2 (hu)
IL (1) IL156779A0 (hu)
MX (1) MXPA03006163A (hu)
NO (1) NO20033145L (hu)
NZ (1) NZ527249A (hu)
PL (1) PL363172A1 (hu)
RU (1) RU2003124653A (hu)
WO (1) WO2002055521A1 (hu)
YU (1) YU55603A (hu)
ZA (1) ZA200305116B (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1375502B1 (en) * 2001-04-05 2007-06-13 Sumitomo Chemical Company, Limited Process for producing 2,6-dihalogenopurine
EP2336133A1 (en) 2001-10-30 2011-06-22 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
DE10252650A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Cyclohexyl-Harnstoff-Derivate
EA010160B1 (ru) 2003-09-18 2008-06-30 Конформа Терапьютикс Корпорейшн Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
WO2005085210A1 (ja) * 2004-03-10 2005-09-15 Ono Pharmaceutical Co., Ltd. ニトリル化合物およびその化合物を有効成分として含有する医薬組成物
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US20090023723A1 (en) * 2005-09-21 2009-01-22 Pharmacopeia Drug Discovery, Inc. Purinone derivatives for treating neurodegenerative diseases
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
AR063142A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7915268B2 (en) 2006-10-04 2011-03-29 Wyeth Llc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
RU2681081C2 (ru) 2007-10-05 2019-03-04 Верастэм, Инк. Пиримидинзамещенные производные пурина, фармацевтическая композиция на их основе, способ ингибирования протеинкиназ, способ лечения или профилактики заболеваний, чувствительных к ингибированию протеинкиназ, и способ лечения пролиферативных заболеваний
GB0906579D0 (en) * 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
RU2506264C2 (ru) 2009-04-03 2014-02-10 Вэрастэм, Инк. Пиримидин-замещенные пуриновые соединения в качестве ингибиторов киназы (или киназ)
EP3011974B1 (en) 2011-06-02 2018-08-08 University Of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
WO2012172043A1 (en) * 2011-06-15 2012-12-20 Laboratoire Biodim Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections
PL2840083T3 (pl) * 2012-04-17 2018-01-31 Astellas Pharma Inc Bicykliczny aromatyczny związek heterocykliczny zawierający azot
US10870816B2 (en) 2016-11-18 2020-12-22 The Procter & Gamble Company Fabric treatment compositions having low calculated cationic charge density polymers and fabric softening actives and methods for providing a benefit
MX2019005825A (es) * 2016-11-18 2019-07-10 Procter & Gamble Composiciones para el tratamiento de telas y metodos para proporcionar un beneficio.
JP7137225B2 (ja) * 2017-08-21 2022-09-14 国立大学法人三重大学 非ヒト哺乳類の脳梗塞モデルによる観察方法及び非ヒト哺乳類の脳梗塞モデルによる観察装置
CN107903274A (zh) * 2017-12-28 2018-04-13 窦玉玲 一种胺类化合物及其在抗肿瘤药物中的应用
US20220380310A1 (en) * 2019-07-01 2022-12-01 Ligang Qian P2x7r antagonists
KR20210061202A (ko) * 2019-11-19 2021-05-27 일동제약(주) 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도
US11787775B2 (en) * 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
US11806350B2 (en) 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3630997A (en) * 1970-05-04 1971-12-28 Paul M Craven Curable epoxy resin compositions and method of preparing same
US5064745A (en) * 1988-02-25 1991-11-12 Mitsubishi Paper Mills, Ltd. Method for making lithographic printing plate
US5403932A (en) * 1988-05-25 1995-04-04 Research Corporation Technologies, Inc. Phosphoramidates useful as antitumor agents
US5968989A (en) * 1991-12-18 1999-10-19 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
DE4330735A1 (de) * 1993-09-10 1995-03-16 Wacker Chemie Gmbh Hydrophile Gruppen aufweisende Organopolysiloxane
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
HRP980375A2 (en) 1997-07-03 1999-04-30 Argyrios Georgios Arvanitis Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
AU1251499A (en) * 1997-11-26 1999-06-15 Cerebrus Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
CA2315736A1 (en) 1998-01-05 1999-07-15 Eisai Co., Ltd. Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus
JPH11279193A (ja) * 1998-03-24 1999-10-12 Akira Matsuda アデノシン誘導体
GB9819382D0 (en) * 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9819384D0 (en) * 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9915437D0 (en) * 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
KR100694684B1 (ko) 1999-07-02 2007-03-13 에자이 알앤드디 매니지먼트 가부시키가이샤 축합 이미다졸 화합물 및 당뇨병 치료약
KR20020093950A (ko) * 2000-04-26 2002-12-16 워너-램버트 캄파니 아형 선택적인 ｎｍｄａ 수용체 길항제로서의시클로헥실아민 유도체
US6903238B2 (en) * 2001-12-13 2005-06-07 Wyeth Substituted indenones as estrogenic agents
US6946005B2 (en) * 2002-03-27 2005-09-20 L'oreal S.A. Pyrrolidinyl-substituted para-phenylenediamine derivatives substituted with a cationic radical, and use of these derivatives for dyeing keratin fibers
DE10326303A1 (de) * 2003-06-11 2004-12-30 Celares Gmbh Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung
CN101103026A (zh) * 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
PL1934243T3 (pl) * 2005-09-09 2011-10-31 Boehringer Ingelheim Int Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych
US7875609B2 (en) * 2005-11-25 2011-01-25 Galapagos Sasu Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them
US8143236B2 (en) * 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
KR20090029827A (ko) * 2006-07-20 2009-03-23 제네랩스 테크놀로지스, 인코포레이티드 폴리사이클릭 바이러스 억제제

Also Published As

Publication number Publication date
WO2002055521A1 (en) 2002-07-18
DE60236719D1 (de) 2010-07-29
JP4284069B2 (ja) 2009-06-24
MXPA03006163A (es) 2003-09-16
US20040102459A1 (en) 2004-05-27
EP1349857A1 (en) 2003-10-08
CN1617871A (zh) 2005-05-18
US7452894B2 (en) 2008-11-18
CA2433858A1 (en) 2002-07-18
IL156779A0 (en) 2004-02-08
AU2002217331B2 (en) 2006-06-29
BR0206561A (pt) 2004-06-22
PL363172A1 (en) 2004-11-15
KR20030079945A (ko) 2003-10-10
NO20033145L (no) 2003-09-09
US20060270691A1 (en) 2006-11-30
YU55603A (sh) 2006-05-25
JP2004517874A (ja) 2004-06-17
CA2433858C (en) 2010-12-14
NZ527249A (en) 2005-04-29
RU2003124653A (ru) 2005-01-10
GB0100623D0 (en) 2001-02-21
ATE471323T1 (de) 2010-07-15
NO20033145D0 (no) 2003-07-09
EP1349857B1 (en) 2010-06-16
ZA200305116B (en) 2004-07-01
CZ20031956A3 (cs) 2003-11-12

Similar Documents

Publication Publication Date Title
HUP0402504A2 (hu) Purinszármazékok, mint purinerg receptor antagonisták
HUP0401047A2 (hu) Triazolo[4,5-d]pirimidin-származékok, alkalmazásuk purinergikus receptor-antagonistákként és a vegyületet tartalmazó gyógyszerkészítmények
HUP0400918A2 (hu) Pirazolin-származékok alkalmazása sejtburjánzásos betegségek megelőzésére és/vagy kezelésére szolgáló gyógyszerkészítmények előállítására
HUP0004807A2 (hu) Vérlemezkéből származó növekedési faktort és/vagy P56lck tirozin kinázokat gátló hatású kinolin- és kinoxalin-vegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények
WO2002040486A3 (en) METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS
MY126862A (en) Purine derivatives inhibitors of tyrosine protein kinase syk
DE60228414D1 (de) Pyrrolo 2,3-d pyrimidine und deren verwendung als purinreceptor antagonisten
HUP0302167A2 (hu) Metabotropikus glutamát receptor antagonista hatású kinolinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
HUP0401638A2 (hu) Daganatellenes hatású tiofén- és tiazolszulfonamid származékok, valamint ezeket tartalmazó gyógyászati készítmények
CA2474192A1 (en) Nicotinamide derivates useful as p38 inhibitors
DK1412354T3 (da) Derivater af triazolylimidazopyridin og af triazolylpurinerne, der er egnede som ligander for adenosin A2a?-receptoren og deres anvendelse som medikamenter
DK1107973T3 (da) Hidtil ukendte thieno(2,3-D)pyrimidindioner, fremgangsmåde til deres fremstilling og anvendelse deraf i terapi
GB0100620D0 (en) Chemical cokpounds V
DK1095040T3 (da) Hidtil ukendte benzoxazoler med PDE-inhiberende aktivitet
HUP0400464A2 (hu) Adenozin analógok inzulinrezisztencia szindróma és diabétesz kezelésére
HUP0401444A2 (hu) Kombinált LH és FSH agonista aktivitással rendelkező tieno[2,3-d]pirimidinek, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
AP2001002251A0 (en) 2-aminopyridines containing fused ring substituents.
HUP0103099A2 (hu) N-Szubsztituált aza-bicikloheptán-származékok, előállításuk és alkalmazásuk

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees